Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170114 | 0.88 | PRKCA (0.42) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL4672250 | 0.84 | MMP1 (0.37) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL4672256 | 0.84 | CTSK (0.38) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL27863693 | 0.83 | MMP1 (0.39) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL4680238 | 0.83 | MMP1 (0.36) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL4677710 | 0.83 | MMP1 (0.36) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL4677707 | 0.83 | MMP1 (0.36) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL4680243 | 0.83 | CTSK (0.37) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL19105218 | 0.83 | MMP1 (0.36) | MMP1MMP9MMP2MMP12CTSK | |
| SCHEMBL11301626 | 0.80 | PRKCA (0.37) | PRKCAPOLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373962-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF BIRMINGHAM (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230373962-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF BIRMINGHAM (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-8741931-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-03 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885MMP1 4282/4885MMP9 3280/4885 |
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885MMP1 4282/4885MMP9 3280/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885MMP1 4282/4885MMP9 3280/4885 |
| US-20230373962-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | PCNA, DDX1, DDX18 | PRKCA 4488/4885MMP1 4194/4885MMP9 3203/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCA 25/4885MMP1 4282/4885MMP9 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.